Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PDXK | O00764 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397038 | 0.84 | POLB (0.37) | POLBCYP2C19HTTMAPK1THRB | |
| SCHEMBL5656943 | 0.79 | POLB (0.36) | POLBCYP2C19HTTMAPK1THRB | |
| SCHEMBL3763823 | 0.77 | — | — | |
| SCHEMBL7248981 | 0.76 | MAPT (0.35) | POLBCYP2C19HTTMAPK1ALDH1A1 | |
| SCHEMBL5657557 | 0.75 | POLB (0.33) | POLBCYP2C19HTTMAPK1 | |
| SCHEMBL6952106 | 0.75 | MAPK1 (0.44) | POLBCYP2C19HTTMAPK1 | |
| SCHEMBL5654666 | 0.72 | MLYCD (0.33) | POLBALDH1A1 | |
| SCHEMBL1752323 | 0.71 | GPR35 (0.40) | POLBMAPK1ALDH1A1NPC1KMT2A | |
| SCHEMBL25283654 | 0.70 | CYP1A2 (0.35) | POLBCYP2C19HTTMAPK1ALDH1A1 | |
| SCHEMBL25283653 | 0.70 | CYP1A2 (0.35) | POLBCYP2C19HTTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6630593-B1 | A process for preparing a 1-substituted 5-hydroxymethylimidazole of the formula: wherein R represents alkyl, hydroxyalkyl, allyl, or substituted or unsubstituted arylmethyl or diarylmethyl, comprising the step of reacting a | LG CHEM INVESTMENT LTD. (KR) | 2003-10-07 | — | — | US | disclosed |
| EP-1255737-A4 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD (KR) | 2003-04-16 | — | — | EP | disclosed |
| EP-1255737-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG Chem Investment, Ltd. (KR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001017974-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD. (KR) | 2001-03-15 | — | — | WO | disclosed |
| EP-0146228-B1 | SUBSTITUTED 2-MERCAPTO-IMIDAZOLES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1988-01-20 | — | — | EP | disclosed |
| US-4584383-A | Substituted 2-mercapto-imidazoles and their preparation | FARMOS YHTYMA-OY (FI) | 1986-04-22 | — | — | US | disclosed |
| EP-0146228-A1 | Substituted 2-mercapto-imidazoles and their preparation and use | Farmos-Yhtyma Oy (FI) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | POLB 3578/4885CYP2C19 70/4885HTT 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.